Transient Ischemic Attack Epidemiology and Management

Transient ischaemic attack (TIA) represents a brief episode of neurological dysfunction caused by focal cortical or retinal ischaemia without acute infarction. Globally, the annual incidence of TIA varies between 20 and 40 per 100,000 population, with higher rates observed in older age groups and in regions with a high prevalence of vascular risk factors such as hypertension, diabetes and atrial fibrillation. Although the symptoms resolve within 24 hours by definition, the early risk of subsequent stroke can exceed 10% within 90 days if no intervention is instituted. Contemporary practice emphasises rapid assessment in specialised clinics or emergency settings to stratify risk and initiate secondary prevention. Acute management includes prompt brain and vascular imaging, cardiac evaluation and initiation of antithrombotic therapy alongside rigorous control of blood pressure, lipid levels and glycaemia. Risk stratification tools—initially time-based scores such as ABCD2 and more recently tissue-based definitions using diffusion-weighted imaging—guide intensity of monitoring and treatment pathways. Secondary prevention extends to carotid endarterectomy for symptomatic stenosis, anticoagulation for atrial fibrillation and lifestyle interventions. Integrating predictive algorithms, streamlined clinical protocols and quality-improvement programmes has driven reductions in early recurrent stroke, hospital bed-days and long-term disability, underscoring the global importance of TIA management in mitigating the burden of cerebrovascular disease.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Transient Ischemic Attack Epidemiology and Management publication trend

The graph below shows the total number of articles in transient ischemic attack epidemiology and management across all publications each year (not limited to Nature Index journals).

Technical terms

Transient ischaemic attack (TIA): A transient episode of neurological dysfunction caused by focal ischaemia without acute infarction, typically resolving within 24 hours.

ABCD2 score: A clinical tool using Age, Blood pressure, Clinical features, Duration and Diabetes status to estimate early stroke risk after TIA.

Diffusion-weighted imaging (DWI): A magnetic resonance technique detecting cytotoxic oedema, used to distinguish tissue-based TIAs from minor strokes by visualising acute infarctions.

Antithrombotic therapy: Pharmacological treatment including antiplatelet agents or anticoagulants aimed at preventing clot formation and reducing recurrent ischaemic events.

Secondary prevention: Strategies employed after an initial TIA to lower the risk of recurrent cerebrovascular events, encompassing lifestyle modification, pharmacotherapy and revascularisation when indicated.

References

1. A Deep Learning System to Predict Recurrence and Disability Outcomes in Patients with Transient Ischemic Attack or Ischemic Stroke. Advanced Intelligent Systems (2023).
2. Processes of Care Associated With Risk of Mortality and Recurrent Stroke Among Patients With Transient Ischemic Attack and Nonsevere Ischemic Stroke. JAMA Network Open (2019).
3. Diagnosis of non-consensus transient ischaemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis. The Lancet (2021).
4. Prognostic value of “tissue-based” definitions of TIA and minor stroke: Population-based study. Neurology (2019).